Giuseppe De Rosa graduated in 1997 in Pharmaceutical Chemistry and Technology at the University of Napoli Federico II. In 2001 he completed a Ph.D. in Pharmaceutical Technology with a dissertation with the title “Delivery of biotechnological drugs by biodegradable microspheres”, with research activity carried out in part at the University Paris-Sud of Chatenay-Malabry (France). From 1999 to 2002, he carried out research activity at the University Paris-Sud of Chatenay-Malabry (France). From 2002 Dr De Rosa was assistant professor at the Faculty of Pharmacy – University of Naples Federico II. From 2014, Dr De Rosa is associate professor at the Department of Pharmacy, University of Naples Federico II. In the same year, he received the national scientific qualification as full professor.

Professor Moustapha Hassan is currently director of Preclinical Laboratory, the preclinical research facility at Karolinska University Hospital, Huddinge, Sweden, as well as Professor of Transplantation Research at Karolinska Institutet Huddinge, Stockholm, Sweden. He is a consultant to several hospitals in Sweden and many hospitals in Europe for personalized treatment prior to stem cell transplantation and treatment for hematological malignancies. His particular focus has been on increasing treatment efficacy and reducing side effects for transplanted children, and on optimizing treatment with busulfan/cyclophosphamide in stem cell transplantation. Professor Hassan developed a liposomal formulation enabling intravenous administration which is currently undergoing clinical trials. Professor Hassan’s current research projects focus on personalizing treatment through genome analysis, nanomedicine and improvement in pre-transplant medicine.

Dr Freitas has been at the Faculty of Pharmaceutical Sciences Ribeirao Preto from the Univesity of Sao Paulo since 1989. He got his MSc and PhD in Chemical Process Engineering at the National University of São Carlos, Brazil. Dr Freitas was a visiting scientist at the Chemical and Bio-resources Engineering Departament from the University of British Columbia, Vancouver, Canada, during 1997-1999. Since 1989 he has been engaged in undergraduate and graduate education in pharmaceutical sciences and his research is devoted to pharmaceutics and pharmaceutical process technology. Dr Freitas hás authored more than 100 peer-reviewed papers, 22 book chapters, and 7 patents.

Dr. Anzenbacher is a Professor at Department of Pharmacology, Palacky University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic. He is has been working in the field of drug metabolism since 1976. Dr. Anzenbacher served for eight years also as a Director and a Vice-Director of the Institute of Experimental Biopharmaceutics (Czech Academy of Sciences-PROMED Joint Institute). He has authored more than 150 manuscripts, 2 patents, and co-edited and contributed to a monograph "Metabolism of Drugs and other Xenobiotics." Dr. Anzenbacher is a member of editorial board of several profiling Journals as „Drug metabolism and Distribution“ or „Xenobiotica“.

Dr. Bandiera is a Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He received a Ph.D. degree in biological chemistry from the University of Guelph, Canada in 1982 and completed postdoctoral training (1983-1986) at the Roche Institute of Molecular Biology in Nutley, New Jersey. Dr. Bandiera has been at the University of British Columbia since 1986 and is involved in undergraduate and graduate education and research. His research is focused mainly on hepatic drug metabolism and environmental toxicology. Dr. Bandiera has authored more than 100 scientific papers, as well as several book chapters.

Charles, board certified in general psychiatry, is founder and president of Beasley Pharmaceutical and Biotechnology Consulting, LLC. He worked in clinical development and drug safety for Eli Lilly for 27 years, retiring as Distinguished Lilly Scholar in 2015. His work included late stage development with fluoxetine, olanzapine, atomoxetine, duloxetine, tadalafil.

Charles has published over 95 peer-reviewed articles. He is an inventor on eight olanzapine patents. Memberships include AOA and the ASCP. He is a fellow of the APA, the ACPsych, the ACNP, and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the UK

Full Professor of Pharmacy and Pharmaceutical Technology. University of Seville. Head of the Iberoamerican-Swiss Center for Development of Dosage Forms of the University of Seville. CEO of Cronofarma SL, Spin-off Company for development of pharmaceutical formulations. More than 20 awards for research and teaching in Spain, USA, Cuba and Switzerland. Foreign Member of the Swiss Academy of Pharmaceutical Sciences. Main research field: Design and Optimization of Controlled Drug Delivery Systems: 100 Scientific papers, 2 Book chapters, Supervisor of 11 PhD Thesis, 52 Research Projects. Reviewer for 25 scientific journals. Member of Editorial Board of 6 of them. More than 40 Invited Lectures since 1997, in countries as: Argentina, Brazil, China, Columbia, Cuba, Germany, Italy, Mexico, Peru, Spain, Switzerland, United States and Venezuela.

Dr. Quintana received his Bacterologist degree in 1998. He received MSc in Basic Biomedical Sciences, Universidad de Antioquia, Medellín - Colombia in 2001 and PhD in Pharmaceutical and Food Sciences, Universidad de Antioquia, Medellín - Colombia in 2013. He is a Professor in School of Medicine, Universidad Cooperativa de Colombia Sede Medellín, Medellín – Colombia. His research for the last few years has changed focus from the use of snake toxins by malaria and bacteria, to the use of plant extracts in envenoming for snake, spider and scorpion venom in animal models.

Professor Piotr Czekaj is currently heading the Department of Cytophysiology, Chair of Histology and Embryology at the Medical University of Silesia, Katowice, Poland. He has long-standing experience in the research. His research is focused mainly on drug metabolizing enzymes, including cytochrome P450s, and drug transporters, as well as regenerative medicine. Professor Czekaj is very experienced in the field of histology and experimental toxicology. He has authored and co-authored 66 peer-reviewed articles and more than 140 conference communications. He is involved in under- and postgraduate education and research.

Dr. Bhaskar Chakraborty is a Professor and Head of the Department of Chemistry at Sikkim Government College, Tadong, Gangtok, Sikkim (a deemed university), with 23 years of experience in teaching undergraduate and post graduate chemistry. He has active research experience of 24 years in synthetic organic chemistry and has been the Supervisor of research scholars leading to PhD degree holders for 14 years. He has published around 60 research publications in international and national journals of high repute with good impact factors and is honorary referee of reviewing research manuscripts for various international and national journals. Dr. Chakraborty has also been awarded with many international and national awards.

William K. Chan received his PharmD in 1986 and PhD in Pharmaceutical Chemistry in 1991, both from UCSF. He was a postdoc in the Department of Environmental Toxicology at UC Davis in 1992. He spent 1993-1996 as a postdoc in the Department of Molecular Pharmacology and Biological Chemistry at Northwestern University Medical School. He was faculty at University of the Pacific in 1996, Full Professor in 2007, and Department Chair since 2014. He works on the aryl hydrocarbon receptor signaling and focuses on the understanding of the molecular mechanism for rational drug design.

Dr. Chen is a Full Member and the Director of the High Throughput Bioscience Center at St. Jude Children’s Research Hospital. His laboratory studies the roles of nuclear receptors in therapeutic efficacy and diseases. Previously, Dr. Chen was a Senior Research Investigator at Bristol-Myers Squibb, and a Research Scientist at SAIC-Frederick, National Cancer Institute. He received his PhD from the University of Vermont, and conducted postdoctoral studies at the University of Virginia. Dr. Chen has authored almost 100 manuscripts and multiple patents, and edited “A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery”.

Dr. Civelli is Professor and Chair of the Department of Pharmacology at University of California, Irvine. He holds the Eric L and Lila D Nelson Chair of Neuropharmacology. Previously he was vice president at F. Hoffmann-La Roche, Basel. He is a recognized leader in the field of neuropsychopharmacology. He was the first to clone the D2 dopamine receptor and to discover the diversity of the dopamine receptors, in particular the D4 receptor, but also the A3 adenosine receptors. He spearheaded reverse pharmacology and used it to discover the first new neuropeptide identified by this approach, nociceptin/orphanin FQ and later neuropeptide S. He discovered the receptors for melanin concentrating hormone and for urotensin II. His primary interest is the study of neuropsychiatric disorders, in particular schizophrenia. He has authored more than 200 manuscripts and holds 30 patents.

Dr. Elísio Costa, Ph.D., is currently a Professor in the Department of Biological Sciences (Faculty of Pharmacy) at University of Porto, Porto, Portugal. His skills and expertise mainly lie in the subject areas of Hypertension, Stem Cell Biology, Clinical Nephrology, Hemodialysis, Kidney Transplantation, Science Education, Hematology, Dialysis, etc. Dr. Costa, as an author/co-author, has published over 140 articles in various journals, having more than 1,015 total citations.

Dr. Yusuf Yahaya Deeni is a Translational Researcher and a Senior Lecturer in Biotechnology and Biological Sciences at Abertay University of Dundee, UK. He is a Fellow of the Royal Society of Biology, and his research in molecular systems pharmacology is essentially about understanding and overcoming drug and chemical resistance, including anticancer, antimicrobial, antimalarial, and insecticide/pesticide resistances. His current research interests include investigating malaria control through targeting mosquito defence systems and investigating the role of the antioxidant response, the DNA damage response and the hypoxia response pathways in the etiology and treatment of cancer.

Dr. S.J.S. Flora, Director, National Institute of Pharmaceutical Education and Research, Raebareli, India, got his Ph.D. from CSIR-IITR, Lucknow, India and did post-doctoral associate at Utah State University, USA. He served for 29 years at DRDO, Gwalior, India. Dr. Flora developed a new molecule for arsenic toxicity which was approved by Drug Controller General of India for human trials. He has over 280 research papers, 70 Reviews/Chapters and 3 patents to his credit. He is Member Editorial Board of 29 international journals and has edited 5 books. He is Fellow of National Academy of Sciences and has supervised 25 Ph.D. students.

Dr. Gao obtained a doctorate (M.D.) in Oncology from the Second Military Medical University, Shanghai, China.

Currently Dr. Gao is also an associate professor and associate director of Department of Pharmaceutical Sciences, College of Pharmacy, Second Military Medical University, Shanghai, China. He is also a visiting scholar of Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, US. He has published more than 40 scientific publications, obtained citations more than 800, and is a named inventor of 10 Chinese patents.

Dr. Gentile is a recognized expert in the transglutaminase research area and has a strong background in the molecular biology and biochemical aspects of the transglutaminase (TG) enzymes expression, activity and function. His work has been focused to the tTG (TG2) characterization in normal and pathological cellular events (cell growth and differentiation, adhesion, apoptosis, neurodegeneration) by biochemical and molecular biology studies. Currently dr. Gentile is a Researcher at the Second University of Naples.

Adriana Georgescu (PhD. Habil) is Principal Investigator Grade I and Head of Department of Pathophysiology and Pharmacology in Institute of Cellular Biology and Pathology ‘Nicolae Simionescu’ of Romanian Academy, Bucharest, Romania. She finished Faculty of Physics in University of Bucharest, Romania, and got Specialization in Biophysics. Her studies are focused on the cellular and molecular mechanisms underlying pathophysiological and physiological processes in the cardiovascular system, to define new therapeutic approaches for atherosclerosis regression and prevention of cardiovascular disease events.

Josef Jampilek completed his Ph.D. degree in Medicinal Chemistry at the Faculty of Pharmacy of the Charles University in 2004. In 2004-2011 he worked in expert and managerial posts in the R&D Division of the pharmaceutical company Zentiva. In 2009 he became an Associate Professor of Medicinal Chemistry at the Department of Chemical Drugs at the Faculty of Pharmacy of the University of Veterinary and Pharmaceutical Sciences in Brno. From June 2016 he works at the Department of Pharmaceutical Chemistry of the Faculty of Pharmacy, Comenius University in Bratislava, Slovakia. He is an author/co-author of 27 patents, more than 130 peer-reviewed scientific publications, 7 university textbooks, 15 chapters in monographs and many invited lectures. He received several awards for his scientific results.

Dr. Swati Jagdale, M.Pharm., Ph.D., M.B.A., studied at the University of Pune, Pune, India. She is presently working as Professor and Head, Department of Pharmaceutics at MAEER’s Maharashtra Institute of Pharmacy, MIT Campus, Kothrud, Pune, India. She has worked in research areas of solubility enhancement techniques, floating drug, pulsatile drug delivery, buccal drug delivery, organogels, emulgel, transdermal drug delivery system, SMEDDS, microemulsion based drug delivery, nasal drug delivery, etc. Dr. Jagdale has published more than 70 national and international research articles in reputed journals. In addition, she has three books to her credit.

Frank Jansman studied pharmaceutical sciences at the University Groningen. Subsequently, he was occupied in the Isala clinics Zwolle as a trainee, where he was registered as a hospital pharmacist in 1998. In 2005, he finished his dissertation concerning chemotherapy in colorectal cancer treatment and fullfilled the training programm for clinical pharmacologist. As from 2008, Frank Jansman is director of pharmacy at the Deventer Hospital and trainer for the registration programm for hospital pharmacists. Furthermore, he is associated to the department of Pharmacotherapy and Pharmaceutical Care of the University Groningen as investigator and lecturer. He is author of numerous national and international publications with a particular focus on clinical pharmacology, clinical toxicology and medical oncology.

Haroon Khan has got the degree of B. Pharm (1999), MPhil (2005), Phd (2011) from the Department of Pharmacy, University of Peshawar. He is currently an Associate Professor at Department of Pharmacy, Abdul Wali Khan University Mardan, Pakistan.

His professional experience is about seventeen years 160 publications His research focus is phytomedicines including phytopharmacological and phytochemical investigations of extracts/isolated compounds in collaboration with numerous national and international research groups.The scientific contribution of Dr. Khan has been acknowledged by Pakistan Council for Science and Technology (PCST) and awarded Research Productivity awarded four times 2011-2014. He has also published three books with LAMBERT Academic publishing, Germany. He is also the editorial board member of various international journals. Additional, he is also supervising several post-graduate scholars.

Dr. Gregory Kouraklis obtained an M.D. from the University of Athens, Greece. He had postgraduate education in Greece and USA and he hold the specialty of General Surgery, with special interest in Surgical Oncology. His current position is Chairman of Surgery in the School of Medicine at the National and Kapodistrian University of Athens, Greece

He has published more than 225 scientific publications in peer reviewed international journals, plus 150 in National journals. He is Editor or Editorial Board in 20 journals.

Dr. Philip Chi Lip Kwok is an assistant professor at the Department of Pharmacology and Pharmacy, The University of Hong Kong. He obtained his BPharm (Hons) and PhD in 2002 and 2007, respectively, from the Faculty of Pharmacy, The University of Sydney. He was a research associate in the Advanced Drug Delivery Group in this faculty from 2007-2011. He has 45 peer-reviewed publications and two joint patents in pharmaceutical aerosols and respiratory drug delivery. Dr Kwok co-hosted and chaired the inaugural Inhalation Asia conference in Hong Kong in June 2013. This was the first international conference of its kind in the Asian region. Following its success, he was an organising committee member for the second one held in Shenyang, China, in September 2015.

Dr. Lian Li obtained her Ph.D. degree in 1991 from the University of California at Davis, Davis, CA, USA. Dr. Li is currently Professor and Vice Chair of the Department of Pharmacology at Emory University School of Medicine, Atlanta, GA, USA. Her research interests mainly lie in the subject areas of Vesicular trafficking in neurotransmission, signal transduction, and neurodegenerative diseases. Dr. Li, as an author/co-author, has published over 45 articles in various journals, having a significant number of total citations, i.e. more than 5,870.

Dr. Lum is a Principal Scientist at Genentech, Inc., where he has been employed for approximately 13 years in the Department of Clinical Pharmacology. He has served a leading role in the development and marketing approvals for a variety of small molecule and protein therapeutics, such as trastuzumab (Herceptin IV/SC), erlotinib (Tarceva), bevacizumab (Avastin), pertuzumab (Perjeta) vismodegib (Erivedge), and ado-trastuzumab (Kadcyla). Prior to joining Genentech, Dr. Lum was a tenured Professor of Pharmacy at the University of the Pacific and Associate Director of the Clinical Trials Office in the Stanford University Medical Center. He has published over 100 manuscripts.

Dr. Nabekura is a Professor of Pharmaceutics at School of Pharmacy, Aichi Gakuin University in Nagoya, Japan. Dr. Nabekura received the B.S., M.S. and Ph.D. degrees in Pharmaceutical Sciences from Kyoto University in Kyoto, Japan. He was previously an Associate Professor at Niigata University of Pharmacy and Applied Sciences in Niigata and a Visiting Scholar at University of Washington in Seattle. He has twenty years of research experience in biopharmaceutics and pharmacokinetics, and has authored and co-authored over 60 articles and book chapters. Dr. Nabekura’s research focuses on the role of membrane transporters in health and diseases.

Dr. Prokai-Tatrai is a Professor of Pharmaceutical Sciences at UNT System College of Pharmacy at Fort Worth where she is an award winning researcher and pharmacy educator. Her primary research interest has been on innovative and multidisciplinary projects focusing on medicinal chemistry-driven drug design and delivery into the central nervous system. A best testimony of a very recent success of her lab has been published in Science Translational Medicine describing the very first brain-selective delivery of estrogens based on a unique bioprecursor prodrug approach. She has six issued US patents and has been an editorial board member of numerous journals and an academic editor of a successful special issue on neuroprotection.

Shailendra K. Saraf has done B. Pharm., M. Pharm., Ph.D., LL.B. He is a Professor of Pharmaceutical Chemistry and presently working as Director (Pharmacy), B.B.D.N.I.I.T., Lucknow, INDIA. He has more than twenty six years of industrial, teaching and research experience. His major research interests include Synthetic Medicinal Chemistry, Phytopharmaceutical Chemistry and Nanochemistry. He has published more than 150 papers in national and international journals and conferences, and sixteen books/book chapters. He has delivered more than two dozen invited/plenary lectures and is a recipient of six prestigious awards.

Prof. Singh studied at Dr. H.S. Gour Vishwavidyalaya, Sagar (M.P.), where he received B. Pharm., M. Pharm. and Ph.D. degrees in Pharmaceutical Sciences between 1989 and 1997. Prof. Singh has more than 110 publications to his credit in journals of National and International repute. He has guided thirty eight M. Pharm. dissertations and sixteen research scholars for Ph. D. Prof. Singh has contributed immensely in the field of novel drug delivery systems, herbal formulations and standardization of drugs. His main area of research encompasses both novel as well as conventional oral drug delivery systems.

Dr. Sissung is a staff scientist in the Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute (NIH). Dr. Sissung’s research is centered on pharmacogenomics and inter-individual differences in response to anticancer agents. He is focused on the discovery and/or molecular characterization of gene drug interactions and the clinical translation of laboratory findings. His other research interests include anticancer drug and biomarker development. Dr. Sissung received an M.S. in chemistry from the University of California at Riverside followed by a Ph.D. in genetics from The George Washington University. He has authored over 70 peer-reviewed publications and owns 4 patents.

Dr. Gul Shahnaz is expert in the development of novel targeted drug delivery systems. The high level of her scientific output in several aspects of drug delivery is demonstrated by various publications. Gul Shahnaz is author of thirty-one publications (added impact factor ~ 121; citations 461; H-index 15) which attest to her as an enthusiastic scientist with a profound background in pharmaceutical sciences. Dr. Shahnaz’s research aims to use nanotechnology to create a new system of treatment which allows efficient and more stable administration of the medicine. Her research will also look to determine alternative ways of drug intake and to overcome the reduction in the drug’s effectiveness.

Dr. Dinesh Kumar is a Scientist in Natural Product Chemistry and Process Development Division at CSIR-Institute of Himalayan Bioresource Technology, Palampur, India. He obtained his PhD in Pharmaceutical Sciences (Pharmacognosy and Phytochemistry). He is PDF from department of Pharmaceutical Sciences, Tashwane University of Technology, Pretoria, South Africa. He has successfully developed herbal products such as Sukhsar Red Ointment (Indus Health Care Pvt. Ltd). He has a rich experience in areas of Herbal drug development, analytical chemistry, Natural product chemistry and Ethnopharmacology (as evidenced by 65 reputed research articles and one book chapter). His current H-index is 14. In 2016, He received Dr. PD. Sethi merit certificate for two publications (Anchrom, Pvt. Ltd). He is editorial board and advisory committee member of various Journal.

Born in Venice, MD degree in Padua and PhD in Gastroenterology in Trieste. Sabbatical periods in The Netherlands, US and Canada, visiting professor in US, Canada, Indonesia, Argentina and different European countries. Previously Head of the Liver Clinic and of the Department of Medicine, Trieste Medical Hospital and Professor of Gastroenterology at the University of Trieste. Currently Scientific Director of the Liver Research Center in Trieste. Twice awarded with Honorary Degree for his scientific commitment in Argentina. Research interests: bilirubin, neonatal jaundice, metabolic liver diseases, HCC, stem cells in HCC. H-Index = 60.

Dr Minaketan Tripathy was born in the village Padmabati, State Odisha, India, in 1978. He obtained his bachelor, master (Pharmaceutics) and doctoral degrees in the field of Pharmacy in the year of 1998, 2001, and 2006 respectively. After serving different institutes in India, Mina joined the faculty of Pharmacy, Universiti Teknologi MARA, Malaysia as a senior lecturer in March 2008 and established the laboratory of Fundamental of Pharmaceutics. Mina believes in trans-disciplinary research and interdisciplinary linkage. The laboratory attracted many research grants, engaged with supervision of research students and published several scientific articles in journals of repute and as well conference proceedings.

Dr. Santos is Parasitologist/Cell biologist and General Secretary of the Brazilian Society for Parasitology. He has experience in ​​protozoan parasite ultrastructure, with patents on antiparasitic chemotherapy. Currently he is a senior researcher in Public Health at Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC-FIOCRUZ), National Research Council (CNPq) research fellow. Dr. Santos was a former vice-president of the Brazilian Society for Microscopy and Microanalysis, and Parasitology coordinator at Federal University of Rio de Janeiro, Brazil.